triazolopyridine compounds as inhibitors of the kinase PIM

Compound of general formula I: or a pharmaceutically acceptable salt thereof, wherein: A is OR10 or NR11R12 it; B is H, F, Cl, OR a, (1-6C alkyl) NR b R c, (1-6C alkyl) OH, CH (OH) CH2OH, or (1-4C alkyl); R1 is H, F, Cl, Br, Me, cyclopropyl or CN; R1a, R2, R3 and R4 are independently H, F, Cl, Br, I or CN; R5 and R7 are independently H, F, Me or CN; R6 is H, F, Me, Br, CN, cyclopropyl, phenyl, MeO- or MeOCH2CH2O-; R10 is H, hetCyc 1, - (1-3C alkyl) hetCyc 1a, hetCyc 2, (CR17R18) p (CR13R14) CH2NR15R16, - (CR17R18) p (CR13R14) CH2OH, (1-6C alkyl), hetAr 1, (alkyl 1-3C) hetAr 1a, or cycloalkyl (3-7C) substituted with NH2, NH (1-6C alkyl) or N (1-6C alkyl) 2; R11 is H or alkyl (1-6C); R12 is hetCyc 3, (1-6C alkyl) NR15R16, C (O) (1-6C alkyl) NR15R16, (1-6C alkyl) NHC (O) O (1-6C alkyl), or cycloalkyl (4 7C) optionally substituted with OH, NH2, NH (1-6C alkyl) or N (1-6C alkyl) 2; R13 is H, alkyl (1-6C), F or OH, and R14 is H, alkyl (1-6C) or F, or R13 and R14 together with the carbon atom to which they are attached form a carbocyclic ring 3-6 members; each R15, R16, R17 and R18 is independently H or alkyl (1-6C), or each R15, R17 and R18 is independently H or alkyl (1-6C) and R16 is H, (1-6C) , C (> = O) CH2F, CH2CHF2 or CH2CF3.